IGF-1 LR3 in Australia: Research Guide, Mechanism & Where to Buy

IGF-1 LR3 (Insulin-Like Growth Factor-1 Long R3) is a synthetic analogue of the naturally occurring insulin-like growth factor 1 (IGF-1). The "LR3" designation refers to two structural modifications made to the native IGF-1 molecule: an arginine substitution at position 3, and the addition of a 13-amino acid extension peptide at the N-terminus. Together these modifications produce a peptide with approximately 3× the anabolic potency of native IGF-1 and a dramatically extended plasma half-life of 20–30 hours, compared to native IGF-1's half-life of minutes to a few hours.

IGF-1 is produced primarily in the liver in response to growth hormone (GH) stimulation and acts as the principal mediator of GH's downstream anabolic effects. IGF-1 LR3 was developed to study these downstream pathways more conveniently, with a longer-acting profile enabling more stable receptor engagement in research models.

IGF-1 LR3 acts on the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase expressed in virtually every tissue in the body. Binding to IGF-1R triggers downstream signalling through the PI3K/Akt and MAPK/ERK pathways, two of the most extensively studied intracellular cascades in cell growth and survival research.

Key effects studied through IGF-1R activation include:

• Protein synthesis, IGF-1R signalling via PI3K/Akt activates mTORC1, the master regulator of protein synthesis and cell growth
• Glucose uptake, IGF-1 has structural homology to insulin and can activate the insulin receptor; IGF-1 LR3 retains low but measurable insulin-like activity
• Anti-apoptosis, Akt activation suppresses pro-apoptotic signals, maintaining cell survival in research models
• Satellite cell activation, IGF-1R signalling plays a central role in muscle satellite cell activation and proliferation, making IGF-1 LR3 a tool in skeletal muscle biology research

The structural modifications in LR3 significantly reduce binding to IGF binding proteins (IGFBPs), which normally sequester native IGF-1 in circulation and limit its bioavailability. Reduced IGFBP binding is the primary mechanism behind LR3's extended half-life and enhanced potency.

IGF-1 LR3 is used across a broad range of preclinical research disciplines:

• Skeletal muscle biology, one of the most studied applications; research examines IGF-1 LR3's role in muscle fibre hypertrophy, satellite cell activation, and recovery from injury in rodent models
• GH axis research, IGF-1 LR3 is used to dissect the downstream effects of GH signalling independently of GH itself, enabling mechanistic studies of the somatotropic axis
• Cell culture and in-vitro work, widely used in cell culture media as a growth factor supplement; standard in serum-free culture protocols for maintaining cell proliferation
• Bone biology, IGF-1 plays a role in osteoblast activity and bone mineral density; LR3 has been studied in bone healing and osteoporosis models
• Metabolic research, insulin-like signalling and its overlap with IGF-1R pathways is studied in models of insulin resistance and metabolic syndrome

Understanding IGF-1 LR3 requires placing it in the context of the GH/IGF-1 axis. Growth hormone is released from the pituitary → stimulates hepatic IGF-1 production → IGF-1 circulates and acts on peripheral tissues. GH secretagogues like CJC-1295 and Ipamorelin stimulate the upstream end of this axis; IGF-1 LR3 acts at the downstream effector level.

For researchers studying the full GH axis, IGF-1 LR3 allows investigation of downstream signalling independently, useful for separating the direct effects of GH from its IGF-1-mediated effects. See also: CJC-1295 + Ipamorelin research guide and HGH 24IU research guide.

IGF-1 LR3 is supplied as a lyophilised powder. Standard reconstitution:

1. Allow vial to reach room temperature before opening
2. Add bacteriostatic water (0.1% acetic acid or BAC water) slowly down the inside vial wall
3. Gently swirl, do not shake or vortex; IGF-1 LR3 is sensitive to mechanical degradation
4. For a 0.1mg vial with 1mL bacteriostatic water: concentration = 100mcg/mL

Lyophilised IGF-1 LR3 is stable at −20°C for 24+ months. Once reconstituted, store at 2–8°C and use within 14–21 days, shorter than many peptides due to greater instability in solution. Avoid repeated freeze-thaw cycles. Use the reconstitution calculator for precise draw volumes.

Research-grade IGF-1 LR3 is available from Australian peptide suppliers. Key sourcing considerations:

• Lyophilised format, solution-form IGF-1 LR3 has limited shelf stability; lyophilised powder is the appropriate format for research use
• Storage conditions, ensure the supplier stores at −20°C; IGF-1 LR3 is more temperature-sensitive than many peptides
• Purity verification, HPLC certificate of analysis for the specific batch is essential given the compound's activity at low concentrations

OzPeps stocks research-grade IGF-1 LR3 with fast Australia-wide shipping and discreet packaging. View IGF-1 LR3 stock and pricing →

All IGF-1 LR3 products from OzPeps are supplied strictly for in-vitro laboratory and research purposes. Not TGA-approved. Not for human or animal consumption. Researchers are responsible for all applicable regulatory compliance.